CD34 and inflammatory bowel disease: Using acetic acid-induced colitis in rats as an IBD-relevant model, Arafat et al. (2021) showed that nanocurcumin treatment results in an increased number of intestinal CD34+ telocytes, identified in situ based on positivity for CD34 and mesenchymal marker vimentin, and significantly attenuated the severity of this experimental model of colitis.